VELOCITY Failure For Versartis's Lead Drug Sends Shares Into Tailspin
Executive Summary
Versartis's long-acting growth hormone product missed Phase III non-inferiority endpoint, wiping more than 83% of the company's value.
You may also be interested in...
Versartis Links With Teijin In First Licensing Deal
Versartis has signed the first licensing deal for its long-acting growth hormone product, tapping Teijin as a commercial partner in Japan.
FDA lifts hold on Versartis' growth hormone; shares rocket
Shares of Versartis rocketed 33.2% on 6 July after the FDA lifted the partial clinical hold on the firm's investigational new drug application for its long-acting form of recombinant human growth hormone (rhGH) VRS-317, which is being investigated to treat growth hormone deficiency (GHD).
10 Clinical Trials To Watch Out For In 2023
Scrip surveys the Phase III clinical trial readout landscape and picks 10 of the more interesting studies set to report in 2023, with a few added extras. AstraZeneca, Novo Nordisk, Novartis and Roche feature heavily.